Different patterns and specific outcomes of large-vessel involvements in giant cell arteritis.


Journal

Journal of autoimmunity
ISSN: 1095-9157
Titre abrégé: J Autoimmun
Pays: England
ID NLM: 8812164

Informations de publication

Date de publication:
09 2019
Historique:
received: 26 02 2019
revised: 06 05 2019
accepted: 14 05 2019
pubmed: 28 5 2019
medline: 22 8 2020
entrez: 28 5 2019
Statut: ppublish

Résumé

Large-vessel involvement (LVI) in giant cell arteritis (GCA) includes different clinical and imaging patterns that are rarely described separately at diagnosis and whose specific cardiovascular outcomes are unknown. We conducted a nationwide retrospective study and included GCA patients with LVI demonstrated on imaging at diagnosis between 2007 and 2017. We analyzed the prognosis of three different imaging patterns of LVI present at diagnosis, with some of them overlapping but with the first one present in all patients: 1) inflammation of the aorta and/or its branches; 2) dilation of the aorta; and 3) stenosis of the aortic branches. A control group of GCA patients without LVI was constituted. We included 183 patients with LVI and 105 controls without LVI. Altogether, among the 183 patients who all showed inflammation of the aorta and/or its main branches, concomitant aortic dilation and large-vessel stenosis were observed in 27 (15%) and 55 (30%) patients, respectively. During the follow-up period, new cardiovascular events occurred in 49% and 11% of LVI patients and controls, respectively (p < 0.0001). Inflammation of the aorta and/or its branches (HR: 3.42 [2.09-5.83], p < 0.0001) and large-artery stenosis (HR: 2.75 [1.80-4.15], p < 0.0001) were independent predictive factors of new cardiovascular events. Conversely, the use of an immunosuppressant besides corticosteroids was a protective factor against new cardiovascular events (HR: 0.44 [0.29-0.66], p < 0.0001) and the development of aortic dilation (HR: 0.43 [0.23-0.77], p = 0.005). This study suggests different forms of cardiovascular events according to the initial imaging pattern of LVI.

Identifiants

pubmed: 31130367
pii: S0896-8411(19)30106-4
doi: 10.1016/j.jaut.2019.05.011
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102283

Informations de copyright

Copyright © 2019. Published by Elsevier Ltd.

Auteurs

Hubert de Boysson (H)

Department of Internal Medicine, Caen University Hospital, Caen, France; Normandie Univ, UNICAEN, CHU de Caen Normandie, 14000, Caen, France. Electronic address: deboysson-h@chu-caen.fr.

Eric Liozon (E)

Department of Internal Medicine and Clinical Immunology, Limoges University Hospital, Limoges, France.

Olivier Espitia (O)

Department of Internal Medicine, Nantes University Hospital, Nantes, France.

Aurélie Daumas (A)

Department of Internal Medicine and Therapeutics, Timone Hospital, Marseille, France.

Mathieu Vautier (M)

AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, Centre de Référence des Maladies Auto-Immunes et Systémiques Rares, Centre de Référence des Maladies Auto-Inflammatoires, Paris, France.

Marc Lambert (M)

Department of Internal Medicine, Lille University Hospital, Lille, France.

Jean-Jacques Parienti (JJ)

Biostatistics and Clinical Research Unit, Caen University Hospital, France.

Brigitte Granel (B)

Department of Internal Medicine and Therapeutics, Timone Hospital, Marseille, France.

Anael Dumont (A)

Department of Internal Medicine, Caen University Hospital, Caen, France.

Audrey Sultan (A)

Department of Internal Medicine, Caen University Hospital, Caen, France.

Alain Manrique (A)

Department of Nuclear Medicine, Caen University Hospital, Caen, France.

David Saadoun (D)

AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, Centre de Référence des Maladies Auto-Immunes et Systémiques Rares, Centre de Référence des Maladies Auto-Inflammatoires, Paris, France; Sorbonne Université;s, UPMC Univ Paris 06, Inflammation-Immunopathology-Biotherapy Department, France; INSERM, Paris, France; CNRS, Paris, France.

Kim Heang Ly (KH)

Department of Internal Medicine and Clinical Immunology, Limoges University Hospital, Limoges, France.

Christian Agard (C)

Department of Internal Medicine, Nantes University Hospital, Nantes, France.

Achille Aouba (A)

Department of Internal Medicine, Caen University Hospital, Caen, France; Normandie Univ, UNICAEN, CHU de Caen Normandie, 14000, Caen, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH